Drugs / NW-101C
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07266298 | Dec 2025 → Dec 2028 expected | metastatic neoplasm | Neowise Biotechnology | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NW-101C | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07266298 ↗ |
| Modality | Cell therapy | “TCR-T Cells” NCT07266298 ↗ |
| Target | PRAME | “PRAME Antigen-targeted TCR-T Cells” NCT07266298 ↗ |